Navigation Links
Experimental drug shows encouraging results in treating most common form of lung cancer
Date:11/1/2013

An experimental cancer drug that has shown promise in the treatment of melanoma has also shown early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death among men and women worldwide.

Dr. Edward Garon, director of thoracic oncology at UCLA's Jonsson Comprehensive Cancer Center, presented the preliminary results of a Phase 1B study of the new drug, called MK-3475, on Oct. 29 at the World Conference on Lung Cancer in Sydney, Australia.

The detailed interim data on safety and activity came from a cohort of 38 patients with non-small cell lung cancer who were treated previously for the disease without positive results. For the study, the patients received MK-3475 every three weeks.

Among the participants, 24 percent responded to the drug, with their tumors shrinking, and the median overall survival rate was 51 weeks. For those who responded, the median response duration the average amount of time their tumors remained shrunk had not been reached at the time of this analysis, so it is at least 62 weeks.

Based on this data, a Phase 2/3 trial comparing two different doses of MK-3475 to standard chemotherapy for lung cancer has begun enrolling patients.

Some cancer cells can evade detection by the immune system by expressing a protein called PD-L1, which interacts with the protein PD-1 to prevent the immune system from seeing the cancer as an invader. MK-3475, an anti-PD-1 immunotherapy drug made by Merck, allows the immune system to properly detect the cancer and to activate T cells the so-called "foot soldiers" of the immune system to attack and kill cancer cells.

The most commonly reported drug-related side effects in the study were rash (21 percent), skin itching (18 percent), fatigue (16 percent), diarrhea (13 percent) and joint pain (11 percent). Most side effects, however, were of low grade.

"These are early results, but we are very encouraged by what we've seen so far with this drug," Garon said. "Lung cancer patients who have disease that has grown after two prior therapies do not have many options, and we are cautiously optimistic that this might be a treatment that improves their chances in the future."

According to the American Cancer Society, approximately 1.4 million people die from non-small cell lung cancer every year. It is the most common type of lung cancer, representing approximately 85 percent of all lung cancer diagnoses.


'/>"/>

Contact: Shaun Mason
smason@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
Source:Eurekalert

Related medicine news :

1. Studies of experimental hepatitis C drug show promise for preventing recurrence in liver transplant
2. ASSURE study of experimental agent to raise HDL yields disappointing and surprising results
3. York physicists offer novel insight into experimental cancer treatment
4. Experimental Drug Shows Benefits Against Melanoma in Early Study
5. Experimental Drugs Show Promise Against Prostate Cancer
6. Experimental Drug Seems to Aid Memory in Mice With Alzheimers
7. Mayo Clinic finds experimental drug inhibits growth in all stages of common kidney cancer
8. Experimental Drug for Hepatitis C Promising, Studies Show
9. Experimental Vaccine Shows Promise for Ovarian Cancer
10. Cisplatin-resistant cancer cells sensitive to experimental anticancer drugs, PARP inhibitors
11. Experimental Staph Vaccine Fails to Work, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... February 28, 2017 , ... Roxanna Cross ... p.m. at the 11th Annual RISE Nashville Summit. RISE Nashville is the healthcare ... and engagement strategies. , The discussion will include best practices for accurate identification ...
(Date:2/27/2017)... ... February 27, 2017 , ... Robert E. Burke, MD, PhD, ... But his impoverished upbringing and life experiences could have led him down a much ... and Inspirational Tales of Parenting, Perseverance and Pediatrics,” Dr. Burke shares a personal account ...
(Date:2/27/2017)... ... ... Carothers is not your typical author. She went from working as a movie extra on ... God, when she isn’t swimming as a performing mermaid. , Her book isn’t typical either. ... offers a comedic look at the dysfunctions of God’s family, before Lucifer was sent to ...
(Date:2/27/2017)... POUGHKEEPSIE, N. Y. (PRWEB) , ... February 27, 2017 , ... ... Society ( ILADS ) has disclosed that despite scientific studies, the Center for Disease ... of chronic Lyme disease . Kenneth B. Liegner, M.D. has compiled into ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair Institute, a ... an upgrade to the company's Yelp listing. Bay Area residents struggling from thinning ... as Platelet Rich Plasma (PRP) therapy, hair transplantation techniques such as Follicular Unit ...
Breaking Medicine News(10 mins):
(Date:2/28/2017)... marks the passing of one if its founding fathers, Dr. Eugene ... the service of scientific and scholarly research. A pioneer in the practice ... the way researchers work with the literature, Garfield passed away suddenly on ... ... Dr. Eugene Garfield, founding father ...
(Date:2/28/2017)... This report provides all the information you ... and activities since 2010. Download the full ... Deals and Alliance since 2010 report provides an in-depth ... world,s leading life sciences companies. On demand ... of the most up to date deal and company ...
(Date:2/28/2017)...   Fourth-quarter 2016 revenues ... million to top end of guidance ... charges in fourth-quarter 2016 associated with the write-down of ... Generics reporting unit Fourth-quarter ... operations; Full-year 2016 reported $14.48 diluted (GAAP) loss per ...
Breaking Medicine Technology: